Pfizer’s COVID-19 Antiviral Pill Fails To Prevent Post Exposure Infection In Household Members
Pfizer Inc (NYSE:PFE) said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was ineffective at preventing the…
Barron’s Latest Picks And Pans: Twitter, Visa, Mastercard, Mohawk Industries, Robinhood And More
Benzinga reviews this weekend's top stories on Barron's, for additional information on the latest market news, Benzinga Pro offers a 24/7 news feed, live chat and charting software.
Syneos Health Shares Jump On Better Than Expected Q1 Earnings, FY22 Outlook
Syneos Health Inc’s (NASDAQ:SYNH) Q1 revenue increased 10.5% on a reported basis and 11.7% on a constant currency (CC) basis to…
FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA
The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as…
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
AstraZeneca Plc’s (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of…
Smith & Nephew Posts Q1 Sales Growth As Elective Procedures Rebound
Smith & Nephew PLC (NYSE:SNN) posted Q1 revenue of $1.31 billion, up 3.3% on a reported basis (including -2.6% currency…
Lower COVID-19 Assay Sales Weighs On Hologic’s Q2 Revenue
Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate…
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years
Moderna Inc (NASDAQ: MRNA)
FDA Gives Green Signal To Pfizer’s Duchenne Gene Therapy Trial
After the FDA lifted its hold on a late-stage study, Pfizer Inc (NYSE:PFE) said it would open the first U.S. trial sites…
Dupixent, Consumer Healthcare Lifts Sanofi’s Q1 Earnings, Backs FY22 Guidance
Sanofi SA (NASDAQ:SNY) posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago.…